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Edited by Horst FeldmannAbstract NF-jB is a collective name given to a family of ubiq-
uitous transcription factors (TFs) activated in response to inﬂam-
matory stimuli and environmental stressors, and required for the
activation of many crucial inﬂammatory and immune response
genes. NF-jB is activated by degradation of its cytoplasmic an-
chors, the IjBs, and subsequent nuclear translocation and accu-
mulation. Once entered in the nucleus NF-jB activates
transcription of hundreds of genes; however, each inﬂammatory
gene must be expressed and turned oﬀ with peculiar kinetics that
suit its speciﬁc function. Chromatin organization plays a major
role in controlling the kinetics of NF-jB recruitment to target
genes and it represents an integration point mediating TF coop-
erativity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: NF-jB; Transcription; Chromatin; Inﬂammation1. Anatomy of the NF-jB system
The ﬁve mammalian NF-jB/Rel proteins contain an amino-
terminal segment of about 300 aminoacids, the Rel-homology-
region (RHR), which mediates DNA-binding, dimerization,
nuclear translocation, interaction with the IjBs and transcrip-
tional regulation [1,2]. Three family members, p65 (a.k.a.
RelA), cRel and RelB contain transcriptional activation do-
mains (TAD) at the carboxy-terminus and therefore are able
to directly activate transcription. The other two members,
p50 and p52, are synthesized as large precursors (p105 and
p100, respectively) with an amino-terminal RHR and car-
boxy-terminal ankyrin repeats: ubiquitin-dependent proteaso-
mal processing removes the carboxy-terminal domain and
releases mature p50 and p52 [3,4]. p50 and p52 lack a TAD
and therefore they form homodimers with no intrinsic ability
to activate transcription. However, they form transcriptionally
active heterodimers in association with p65, cRel and RelB.
Moreover, p52 can activate transcription when complexed to
Bcl-3, an IjB-like molecule with coactivator functions [1].
Dimerization is required for NF-jB binding to DNA and more
than 12 homo- and hetero-dimers have been described [2]. Dif-
ferent dimers are held in the cytoplasm by interaction with spe-
ciﬁc inhibitors: dimers containing p65 or cRel associate with
the IjBs (Inhibitors of jB), which include IjBa, IjBb and IjBe*Fax: +39 02 57489 851.
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doi:10.1016/j.febslet.2006.02.072[5]. IjBs contain an amino-terminal regulatory region that is
phosphorylated in response to stimulation, and carboxy-termi-
nal ankyrin repeats which mediate association with NF-jB di-
mers. Conversely, RelB/p52 does not associate with the IjBs [6]
and is retained in the cytoplasm by p100 [7,8]. IjB-sequestered
complexes are released by activation of the canonical NF-jB
activation pathway (Fig. 1), which depends on the IKKb/
IKK2 subunit of the IjB-kinase (IKK) complex, and on its
non-catalytic partner, IKKc/NEMO [9]. By phosphorylating
two N-terminal serines in the IjBs, IKKb generates a docking
site for the bTrCP proteins, which poli-ubiquitinate the IjBs
and target them for proteasomal degradation, thus liberating
p65- and cRel-containing dimers. Release of p52/RelB [4,10]
occurs through a ‘non-canonical’ pathway requiring the NF-
jB-inducing kinase (NIK), which acts via activation of IKKa
(Fig. 1). In turn, IKKa phosphorylates p100 thus directing its
poli-ubiquitination and processing [11]. This pathway is in-
duced in response to a subset of stimuli such as BAFF,
CD40-L and LTb-R triggering, and it has much slower activa-
tion kinetics than the canonical one. The two pathways redun-
dantly activate the expression of several genes (e.g. G-CSF,
VCAM and TNFa) whose expression is elevated without stim-
ulation in both IjBa/ mice (in which the major activated
complex is p50/RelA) [12] and in mice lacking the carboxy-ter-
minus of p100 but still expressing p52 (in which the major acti-
vated complex is p52/RelB) [13]. On the other hand, analysis of
gene expression induced by LTb-R triggering indicates that in
ﬁbroblasts some genes are non-redundantly regulated by either
of the two pathways [14]. Speciﬁc activation of target genes by
the non-canonical p52/RelB dimers reﬂects their ability to bind
at high aﬃnity some cognate sites that are poorly recognized by
all the other NF-jB dimers [15].2. Many too many: the huge repertoire of jB sites in mammalian
genomes
NF-jB dimers bind a family of 9–11 bp DNA-binding sites
known as jB sites, which represent themajor source of complex-
ity in this system [16]. The jB site sequence, which is convention-
ally represented as G5G4G3R2N1 N0Y+1Y+2C+3C+4
(R = purine, N = any nucleotide, Y = pyrimidine) (Fig. 1) is in
fact highly degenerate, and several jB sites obviously deviate
from this consensus and yet bind some NF-jB species with high
aﬃnity. For instance, the nonameric CD28 response element
(CD28RE) in the interleukin 2 (IL-2) enhancer (AGA-
AATTCC) eﬃciently binds c-Rel homodimers, and the jB siteblished by Elsevier B.V. All rights reserved.
Fig. 1. Canonical and non-canonical NF-jB activation pathways. Left: the canonical pathway requires IKKb/IKK2 and its non-catalytic binding
partner NEMO/IKKc. IKKb targets two amino-terminal serine residues in the IjBs, whose phosphorylation triggers poly-ubiquitination and IjB
degradation. This pathway controls the release of all the p65- and c-Rel-containing dimers, which bind canonical jB sites (shown below). Right: the
non-canonical NF-jB activation pathway requires NIK and IKKa/IKK1 and controls proteasomal processing of p100, thus generating p52, which is
a preferential RelB binding partner. Since p52/RelB has a very low aﬃnity for the IjBs, this pathway is entirely controlled by inducible p100
processing. The p52/RelB dimers are peculiar in their ability to bind both canonical sites and atypical jB sites with undetectable aﬃnity for canonical
NF-jB dimers.
2844 G. Natoli / FEBS Letters 580 (2006) 2843–2849in the murine urokinase plasminogen activator gene promoter
(AGGAAAGTAC) is recognized at high aﬃnity by p65/c-Rel
heterodimers. Sequence variation most commonly occurs in
the 3 0 half of the site, while the 5 0 half (GGGAA) tends to be rel-
atively invariant [16].
A reliable estimate of the number of jB sites in mammalian
genomes is still unavailable, mainly because we still do not
know the impact of each nucleotide variation in the jB site
on binding aﬃnity: in simple words, we still do not know all
jB sites. Udalova and colleagues [17] showed that the 256 vari-
ants of the most restrictive jB site consensus sequence, in
which the ﬁrst (G5G4G3) and the last (C+3C+4) nucleotides
are invariant, are represented over 11000 times on human
chromosome 22 (the smallest one in human cells). Since these
256 sequences represent only a fraction of all the possible jB
sites, it can be concluded that potentially functional jB sites
in the human genome are in the order of magnitude of 105.
Although it is possible and likely that many of these sites are
in a non-functional context and may not be available for bind-
ing, it is clear that NF-jB (like most transcription factors
(TFs)) must routinely deal with a very large number of sites.
To obtain an experimental estimate of the frequency of
genomic sites contacted by NF-jB dimers, ChIP-chip assays
have been used. The DNA sequences bound by NF-jB
in vivo have been isolated by chromatin immunoprecipitation
(ChIP) and used to probe a microarray (chip) containing allthe non-repetitive regions of human chromosome 22 [18]. This
approach has demonstrated that in HeLa cells stimulated with
TNFa endogenous p65/p50 heterodimers bind 209 regions on
chr 22. Sixty percent of these regions contain either canonical
or variant jB sites, thus suggesting that in most cases contact
of NF-jB with DNA is direct. The mechanism underlying
NF-jB recruitment to the regions not containing identiﬁable
binding sites remains to be clariﬁed. One possibility is the pres-
ence of deviant jB sites that are not recognized by current
computational tools. Alternatively binding may occur via pro-
tein–protein interactions with other DNA-bound factors. For
instance, it has been shown that NF-jB can be recruited to
interferon responsive genes via association with interferon reg-
ulatory factor 3 (IRF3): at these genes IRF3 binds to a cognate
sequence known as interferon-stimulated response element
(ISRE) and promotes NF-jB recruitment via protein–protein
interactions [19]. Since chromosome 22 is about 1/67th of the
whole genome, extrapolation of these data to the whole
genome indicates the existence of about 14000 functional
and contacted binding sites. This number is likely to be an
underestimation of the actual number of jB sites for the fol-
lowing reasons: ﬁrst, the array was composed of fragments
of 700 bp in average and the size of immunoprecipitated
chromatin fragments was in the same range. Since jB sites
are often clustered, speciﬁc hybridization with one sequence
likely reﬂects binding of p65 to multiple sites within that
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and time-point. Third, the data were obtained in a single epi-
thelial cell type and it is well known that the transcriptional
program induced by NF-jB in other cell types like macro-
phages is much broader. Considering that the number of p65
molecules entering the nucleus upon stimulation has been esti-
mated in a range of 100000–150000 [20], it appears that the
number of functional jB sites and the number of NF-jB
molecules are in a comparable order of magnitude. Then,
how does NF-jB interact and exchange with this large number
of target sites? Recent data support the idea that interactions
of NF-jB with high aﬃnity genomic jB sites occurs on a very
fast timescale, with an average residence time of a few seconds:
this rapid exchange prevents the immobilization of active di-
mers onto the many thousands jB sites that are dispersed in
the genome [21] and provides a satisfactory explanation of
why hundreds of thousands of high aﬃnity jB sites do not eﬃ-
ciently compete for NF-jB species and do not prevent them
from speciﬁcally binding to functional sites in target genes.
Rapid exchange with cognate sites appears to be a common
theme in transcriptional regulation: most, if not all, TFs are
highly mobile in the nucleus and their mobility is accelerated
by mutations that speciﬁcally abrogate sequence-speciﬁc bind-
ing to DNA [22]: therefore, the main determinants of TF
mobility in the nucleus are sequence-speciﬁc interactions with
high aﬃnity sites; by inference, it can be assumed that non-
sequence-speciﬁc contacts with genomic DNA are too short-
lasting to be measured.3. Why jB sites are degenerate and how jB site variability
impacts on the NF-jB response
Like most TFs, also NF-jB is highly tolerant to sequence
variations in the binding sites, being able to bind several
degenerate sequences with comparable aﬃnity. A basic ques-
tion is if this sequence variability among high aﬃnity binding
sites simply reﬂects the functional neutrality of small nucleo-
tide changes or if these variations are biologically relevant
and exploited for regulatory purposes. With the possible
exception of a few RelB-p52 selective sites [15], no obvious di-
mer-site pairs do exist in the NF-jB system (reviewed in [16]).
Several observations are consistent with this view: ﬁrst, no
obvious correlation was found between the sequence of jB
site(s) in target genes and the requirement for a speciﬁc NF-
jB subunit [23]; second, diﬀerent dimers can be exchanged at
the same gene over time [24]; third, some genes are able to re-
cruit all NF-jB proteins with no apparent speciﬁcity [24]. Nev-
ertheless, studies on mutant mice and cells have clearly shown
that each gene requires a speciﬁc combination of NF-jB pro-
teins for activation [23,25]. Recent data start clarifying the
molecular basis for speciﬁcity and explain how a given site
may be linked to the requirement for a speciﬁc NF-jB protein.
c-Rel is highly homologous to p65; yet p65 and c-Rel appear to
regulate largely distinct set of genes (although redundancy at
some genes has been demonstrated) [23,26]. In mouse macro-
phages, only four genes are c-Rel dependent [27]. One of them
is Il12b, which encodes for IL-12 p40, one of the two subunits
of interleukin 12 (IL-12). Although Il12b expression is slightly
reduced in p65/ macrophages, its expression is almost com-
pletely abrogated in c-Rel-deﬁcient macrophages [28], indicat-
ing that no signiﬁcant redundancy occurs at this speciﬁc gene.Smale and coworkers identiﬁed a short sequence within the
RHR of c-Rel that is responsible for c-Rel requirement for
Il12b induction [27]. The RHR contains a 180-amino-acid long
amino-terminal domain (N-RHR) responsible for sequence-
speciﬁc DNA binding and a carboxy-terminal dimerization do-
main (C-RHR) separated by a ﬂexible linker [29]. The N-RHR
of p65 and c-Rel are highly homologous and conversely di-
verge from those of p50 and p52. c-Rel-speciﬁc induction of
IL12b was shown to depend entirely on its N-RHR and in par-
ticular on a short sequence stretch (46 aminoacids) contained
within the region of maximal divergence from p65 (heretofore
referred to as speciﬁcity determining region, SDR). Con-
versely, the transcriptional activation domains (TADs) of
p65 and c-Rel were largely interchangeable, thus indicating
that if c-Rel- and p65-selective coactivators that directly bind
their TADs do exist, they do not critically contribute to spec-
iﬁcity. Interestingly, when the most solvent-exposed residues in
the c-Rel SDR were simultaneously changed to the corre-
sponding p65 residues, the mutant protein retained its ability
to activate IL12b expression: this ﬁnding argues against the
possibility that the c-Rel SDR acts by mediating critical pro-
tein–protein interactions. Then how does it work? A key obser-
vation was that the c-Rel SDR increases the aﬃnity of c-Rel
homodimers (but not c-Rel/p50 heterodimers) not only for
canonical jB sites, but also for sites that diverge from the
canonical consensus. The Il12b promoter contains two jB
sites: the proximal one binds eﬃciently p50/c-Rel and p50/
p65; the distal site resembles the CD28- response element that
binds p50-containing dimers with very low aﬃnity and con-
versely is a preferred c-Rel binder. Therefore one attractive
possibility is that speciﬁc c-Rel requirement depends on its
high aﬃnity interaction with the distal jB site, which is re-
quired for c-Rel-induction of the Il12b promoter.
Two considerations indicate that the c-Rel SDR may aﬀect
binding to jB sites only indirectly: ﬁrst, the N-RHR residues
that contact both DNA bases and the sugar–phosphate back-
bone are conserved between p65 and c-Rel; second, only two
of these residues (K100 and K111) are located within the
SDR. Therefore, it may be assumed that the c-Rel SDR may
promote a selective conformation (maybe a high ﬂexibility) that
endows c-Rel with the ability to recognize deviant jB sequences
at high aﬃnity. The c-Rel SDR is also required for induction of
Il12a in dendritic cells (DCs): remarkably, dependence of this
gene on c-Rel is restricted to DCs and is not observed in murine
macrophages [28,30,31]. If c-Rel dependence reﬂects exclusively
its ability to bind variant jB sites contained in target genes,
then it may be inferred that Il12a activation in DCs and macro-
phages requires alternative jB sites and that the Il12a jB site(s)
used in macrophages can eﬃciently and productively bind other
NF-jB species than c-Rel homodimers.
These observation support the idea that even relatively small
diﬀerences in the aﬃnity of the various NF-jB species for a spe-
ciﬁc jB site may be biologically relevant [17]. Additional exper-
imental evidence supporting this concept comes from studies in
Drosophila. Dorsal (Dl) is a Drosophila NF-jB protein impli-
cated both in development and immune response, which is dis-
tributed in a concentration gradient across the dorso-ventral
axis of the early embryo. Enhancers bearing low aﬃnity binding
sites for Dl require peak levels of Dl (that are found only in the
ventral mesoderm) to be activated. Conversely, enhancers bear-
ing high aﬃnity sites can be activated in response to low levels of
Dl like those contained in lateral ectoderm [32]. Thus, diﬀerences
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expression. Since diﬀerent types of mammalian cells contain dif-
ferent levels of NF-jB proteins, and since levels of individual
NF-jB proteins are dynamically regulated by environmental
and developmental cues, the possibility exists that similar mech-
anisms operate also in higher eukaryotes.
An additional eﬀect of jB site variability is to impart alter-
native conformations to the bound NF-jB dimer [33]. NF-jB
dimers are surprisingly ﬂexible due to the presence of a short
linker connecting the N-RHR to the C-RHR [29,34]: this lin-
ker allows the N-RHR to rotate and translate in order to opti-
mize the alignment with the DNA sequence of the aminoacids
that make direct contacts with the bases exposed in the major
groove. Any nucleotide variation in the jB site implies that
NF-jB must bend in an alternative fashion to maximize the
contacts with DNA and preserve a high aﬃnity for the site.
Similar to the eﬀects observed for other TFs [35], conforma-
tional eﬀects induced by alternative recognition sites eventually
change the ability of the DNA-bound factor to interact with
transcriptional co-regulators, thus causing diﬀerences in coac-
tivator requirements at diﬀerent promoters.4. Chromatin structure and jB site accessibility
The kinetics of NF-jB recruitment to target genes as evalu-
ated by ChIP is extremely complex and regulated in a cell type-
speciﬁc manner: Some genes recruit NF-jB shortly after its
nuclear entry, while others recruit it tens of minutes to hours
later, in spite of the presence of high-aﬃnity jB sites in their
promoters [36]. For instance, NF-jB recruitment to the IL-6
promoter in LPS-stimulated macrophages occurs more than
2 h after stimulation, while recruitment to the same gene is
very fast in ﬁbroblasts [37]. Since at many genes recruitment
of NF-jB coincides with transcriptional activity [21], alterna-
tive recruitment kinetics directly control the kinetics of gene
induction.
In principle, this temporal level of regulation may be extre-
mely relevant from a biological point of view because it allows
each gene to be induced with peculiar kinetics that suits its spe-
ciﬁc function. For instance, expression by DCs of chemokines
attracting T lymphocytes in the T-dependent areas of lymph
nodes (e.g. ELC/CCL19) is postponed some hours as com-
pared to the induction of chemokines (e.g. IL8/CXCL8)
recruiting granulocytes to inﬂammatory sites [24]. This way
DCs can express IL8 in the periphery shortly after encounter
with microbes, while ELC expression occurs only after migra-
tion to lymph nodes.
The existence of speciﬁc chromatin conﬁgurations that are
non-permissive for NF-jB recruitment may be invoked to ex-
plain how NF-jB is kept from binding immediately and by de-
fault to several genes [36]. The assembly of DNA with core
histone proteins to generate nucleosomes (the basic compo-
nents of chromatin) and the further folding of the nucleosomal
chain into higher order chromatin ﬁbers with various degrees
of condensation poses, in general, a barrier to the recruitment
of TFs to their cognate sites [38]. Yet, each TF is diﬀerent in its
ability to contact target sites embedded in a nucleosomal con-
text. For instance, while the TATA-box binding protein has no
detectable aﬃnity for its target site within a nucleosome [39],
the glucocorticoid receptor (GR) has only a two to ﬁvefoldhigher aﬃnity for nucleosome-free mouse mammary tumor
virus (MMTV) long-terminal repeat (LTR) as compared to
reconstituted MMTV-LTR nucleosomes [40].
Interestingly, incorporation of jB sites in positioned nucleo-
somes only marginally reduced the ability of NF-jB to bind
DNA [41], and high-aﬃnity binding was observed indepen-
dently of jB site location relative to the dyad axis of the nucle-
osome. NF-jB binding did not occur simply as a result of
spontaneous uncoiling of mononucleosomal DNA, since in
this case the reduction in aﬃnity would have been much great-
er, in particular for internally located sites. These data are con-
sistent with the formerly reported ability of NF-jB to bind jB
sites in promoters and enhancers assembled in non-positioned
nucleosomes [42,43]. Although the structural basis for NF-jB
binding to nucleosomal sites are not clear at all (discussed in
[16]), this observation suggests that the simple incorporation
of jB sites in nucleosomes is without any major consequence
on NF-jB binding.
However, the recent demonstration that in LPS-stimulated
macrophages nucleosome remodeling is required for the acti-
vation of both secondary response genes and primary response
genes induced with slow kinetics, provides compelling evidence
that nucleosomes are crucial controllers of the kinetics of acti-
vation of NF-jB-regulated genes [44]. SWI/SNF complexes are
multi-component machineries containing either of two ATPase
catalytic subunits, BRG1 and BRM, and a number of addi-
tional components that exert structural roles or mediate inter-
actions with sequence-speciﬁc TFs [45]. Macrophages depleted
of both BRG1 and BRM showed virtually no impairment in
the induction of genes like MIP-2 (Cxcl2) and TNFa, which
are primary response genes induced with fast kinetics after
LPS stimulation. Conversely, induction of secondary genes
(i.e. genes requiring new protein synthesis for activation, e.g.
IL-6 and IL12b) as well as of primary genes activated with
slow kinetics (e.g. Rantes/Ccl5) was severely impaired, indicat-
ing that nucleosome remodeling at these genes is essential for
transcriptional activation [44]. Recruitment of BRG1 to the
promoters of the genes requiring its activity for induction oc-
curs in an inducible fashion after stimulation, suggesting that
some TFs activated by LPS probably mediate BRG1 associa-
tion with these regulatory sequences. At least two scenarios
can be envisioned: the ﬁrst possibility is that TFs activated
with slow kinetics (in the case of late primary genes) or synthe-
sized in an inducible manner after stimulation (in the case of
secondary genes), bind promoters of inﬂammatory genes and
directly mediate SWI/SNF recruitment thus increasing jB site
accessibility and favoring NF-jB recruitment and subsequent
transcriptional induction. Alternatively, these TFs may favor
NF-jB recruitment by cooperative eﬀects (see below) and inde-
pendently of remodeling: after binding to promoters, NF-jB
mediates SWI/SNF recruitment and removal of inhibitory
nucleosomes, thus triggering transcriptional activation.5. Control of NF-jB function by companion TFs
A widely accepted dogma in transcriptional regulation is
that cooperative eﬀects arising from protein–protein contacts
among TFs are crucial for speciﬁc binding to regulatory re-
gions in vivo. A requirement for cooperative interactions is
suggested by simple considerations: any increase in TF aﬃnity
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non-speciﬁc aﬃnity for non-descript DNA. Therefore, selec-
tive TF recruitment to relevant sites contained within func-
tional regulatory regions must rely on cooperative
interactions among TFs binding to contiguous sites. However,
formal evidence that recruitment of NF-jB to chromatin
in vivo requires cooperative eﬀects provided by partner TFs
is still lacking and it may be very diﬃcult to obtain. In fact,
even the interferon b (IFN-b) enhanceosome, whose in vitro
assembly depends on cooperative interactions between NF-
jB, IRFs, activating TF 2 (ATF-2) and c-Jun, together with
the architectural protein HGM-I(Y) [46], is assembled in a
stepwise fashion in vivo, with activators being recruited asyn-
chronously [47]. This observation rules out the possibility that
the same type of cooperative enhanceosome assembly observed
in vitro also occurs in living cells. Moreover, structural analy-
sis of the subcomplex containing ATF-2/c-Jun and IRF-3
bound to the interferon-b enhancer demonstrated that cooper-
ativity did not arise from protein–protein interactions; instead,
it resulted from conformational changes in the DNA due to
the binding of multiple TFs to overlapping binding sites [48].
In other words, it can be assumed that the ﬁrst TF recruited
to this enhancer induces conformational changes in DNA that
promote subsequent recruitment of the other TFs of the com-
plex. Also in this model the functional outcome is cooperative
binding but it must be assumed that the multiprotein/DNA
complex is assembled in a sequential, step-wise manner.
Possible evidence of cooperative eﬀects in vivo is the observa-
tion that a dominant-negative IRF3 mutant impairs NF-jB
occupancy at the RANTES promoter and, vice-versa, NF-jB
inhibition impairs IRF3 recruitment [49]. However, a kinetic
analysis demonstrating that the two factors are recruited simul-
taneously, as predicted by classical cooperativity models, was
not provided. This raises the possibility that the reciprocal
inﬂuence between NF-jB and partner TFs binding to chroma-
tin may reﬂect more complex mechanisms, as indicated by
in vivo studies on Sp1 and NF-jB. Recruitment of NF-jB to
an intronic enhancer in the SOD2 gene requires the constitutive
binding of the TF Sp1 to a site in the promoter, which is more
than 2 kb distant from the NF-jB-regulated enhancer [50]. In a
reciprocal fashion, p65 binding to a distal promoter region in
the gene encoding the chemokine CCL2 (also known as mono-
cyte chemoattractant protein 1) is required for inducible Sp1
binding to a proximal promoter region [51]. Thus, although
the ultimate functional outcome is cooperation, these eﬀects
can be best described in terms of long-range communication be-
tween TFs bound to non-contiguous regulatory regions.
Analysis of recruitment of NF-jB and companion TFs to
inﬂammatory gene promoters in a system in which NF-jB nu-
clear levels oscillate over time indicates that the recruitment
proﬁle of NF-jB is apparently dissociated from that of its
partners, and that removal of NF-jB from DNA at the end
of each oscillation does not cause the release of companion
TFs, thus arguing against the existence of stable enhanceo-
somes assembled in cooperative fashion [21]. On the other
hand, recruitment of NF-jB to functional genes results in a
detectable reduction of its mobility as compared to non-func-
tional sites, thus indicating that NF-jB is transiently immobi-
lized on chromatin upon transcriptional activation, an eﬀect
that may depend on cooperative interactions [21].
Interactions with partner TFs may have other and more
complex regulatory roles than simply increasing the eﬃciencyof recruitment to DNA. IRF3 [52] provides a paradigm of
how diﬀerential induction of a single TF can impact on the
NF-jB response. IRF3 is an IRF-1 and IRF-2 homolog whose
DNA-binding activity is induced during viral infection via di-
rect phosphorylation by virus-activated kinases, namely TBK1
(TANK-binding kinase, a.k.a. IKKd or NF-jB-activating ki-
nase, NAK) and IKKe (a.k.a. IKKi) [53,54]. IRF3 activation
occurs via a MyD88- independent and TRIF-dependent path-
way in response to TLR3 and TLR4 triggering (receptors for
dsRNA and LPS, respectively), while other TLRs are devoid
of this signaling activity [55–57]. IRF3 induction by LPS and
dsRNA is required for the induction of a set of NF-jB-depen-
dent primary response genes like those encoding the chemo-
kines RANTES and IP10 (CXCL10). IRF3 activity at these
genes is mediated by an ISRE [52] usually located in proximity
of the jB site(s). IRF3 is also required for the induction of
IFNb, whose secretion mediates a secondary response consist-
ing in the induction of typical IFN target genes like Mx1 and
IRF7 [57]. Moreover, IFNb can also contribute to sustain
induction of primary response genes containing an ISRE: in
this case it is possible and likely that IRF3 is replaced by the
IFNb-induced STAT1–STAT2–IRF9 complex. Therefore,
selective control of IRF3 activation speciﬁcally links TLR3
and TLR4 triggering to the induction of a subset of NF-jB-
dependent genes. A second consequence of IRF3 activation
is that it generates a transcriptional surface mediating trans-
repression by glucocorticoids, although the speciﬁc mecha-
nisms controlling this response is controversial [19,58]. The
GR, and to a lesser extent several other nuclear receptors, re-
press NF-jB-dependent transcriptional responses via mecha-
nisms that are still unclear [59]. Ogawa et al. observed that
about one third of TLR4-induced, NF-jB-dependent genes
that are inhibited by glucocorticoids also require IRF3 for
induction [19]. IRF3 can directly bind p65/RelA thus making
stable complexes [60]: the IRF3/NF-jB complex can be re-
cruited to DNA either via an ISRE or via a jB site. When
the complex is recruited via an ISRE, p65 does not contact
DNA directly but it acts as a coactivator absolutely required
for IRF3-dependent transcriptional activation. In a reciprocal
fashion, some IRF3-dependent genes do not contain an ISRE:
at these genes IRF3 acts as a required coactivator that is re-
cruited indirectly via association with jB-site-bound p65. Oga-
wa et al. found that the GR DNA-binding domain directly
contacts the N-RHR of p65, thus disrupting the p65-IRF3
complex and blocking the induction of IRF3-dependent genes
(irrespective of the direct or indirect mechanism of IRF3
recruitment). Reliance on the IRF3/p65 interaction, which
selectively occurs at some NF-jB-dependent genes, contributes
to explain how glucocorticoids can exert gene-speciﬁc (rather
than global) eﬀects on the NF-jB response. The results by
Ogawa et al. also imply that since a large fraction (about
70%) of GR-repressed genes are not IRF3-dependent, mecha-
nisms for GR-mediated trans-repression must be heteroge-
neous and gene-speciﬁc, thus suggesting that the each one of
the many proposed mechanisms of trans-repression may only
apply to subsets of NF-jB-dependent genes. Reily et al. [58] re-
trieved IRF3 from a two-hybrid screening in which GRIP1, a
member of the steroid receptor coactivator family [61], was
used as a bait. IRF3 was shown to compete with GR for
GRIP1 binding in mammalian cells and to require GRIP1
for full transcriptional competence: the authors of this study
proposed that activated GR binds GRIP1, thus reducing its
2848 G. Natoli / FEBS Letters 580 (2006) 2843–2849availability; therefore IRF3 cannot activate eﬃciently its target
genes. At the same time, the GR–GRIP1 complex may act to
directly trans-repress NF-jB and AP-1 target genes.
A more classical transcriptional synergism involving NF-jB
and CREB has been recently described as a key component of
the macrophage anti-apoptotic response. Survival of activated
macrophages critically depends on both NF-jB and the p38
MAP kinase [62]. Work by Karin and coworkers [63] showed
that p38 controls the induction of a subset of NF-jB-regulated
genes by triggering MSK1/2-dependent phosphorylation of
CREB, whose binding sites are highly represented in a subset
of NF-jB/p38-coregulated genes. The dependence of survival
genes on both NF-jB and p38 speciﬁcally links macrophage
survival to the induction of both pathways and provides a
simple paradigm of how parallel signaling events generate a
transcriptional crosstalk.6. Conclusions
In spite of being one of the most extensively studied families
of eukaryotic TFs, NF-jB is still far from being completely
understood. Areas of intense investigation will include the
analysis of inhibitory nucleosome modiﬁcations controlling
NF-jB recruitment to target genes; the interplay between
NF-jB and companion TFs; the identiﬁcation of the essential
co-regulators and co-repressors acting as interfaces between
NF-jB and the transcriptional machinery. Given the central
role of NF-jB in vital responses (like the elimination of path-
ogenic microbes) and in chronic diseases, including cancer, it is
warranted that such issues will magnetize the eﬀorts of many
researchers.References
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